ASKA Pharmaceutical HoldingsASKA Pharmaceutical Holdings CO., Ltd.4886東証プライム医薬品FY ending Mar 2026, consolidated, J-GAAP
Revenue by business segment, and the profit each one keeps.
Geographic revenue reported in annual filings
No geographic revenue breakdown was disclosed.
※ Segment figures include inter-segment sales and do not sum to the company total
X-axis: segment revenue CAGR. Y-axis: latest operating margin. Bubble size: revenue.
Bubble size represents latest revenue. Segments without a CAGR are placed at the left edge; their horizontal position is not a growth value. Color indicates positive or negative margin.
| Segment | Revenue CAGR | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|---|
| pharmaceutical business | +3.8%4y | 50,79110.0% | 53,57910.8% | 56,01613.7% | 56,65511.2% | 58,92712.1% |
| animal health business | +6.8%4y | 5,6306.7% | 6,6606.1% | 6,6642.9% | 7,2464.1% | 7,3344.7% |
| Other | +5.0%4y | 185-8.6% | 220-2.7% | 162-77.2% | 2370.8% | 225-5.8% |
| Oversea business | N/A | — | — | — | — | 4,6402.3% |
Top: revenue. Bottom: operating margin.
EDINET (FSA Japan)
有価証券報告書－第5期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
有価証券報告書－第4期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
有価証券報告書－第3期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
有価証券報告書－第2期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
有価証券報告書－第1期(令和3年4月1日－令和4年3月31日)
Extracted from XBRL: 52 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.